Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression-Reference-Cited by-同舟云学术

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

Published:2013-10-23 Issue:208 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Hassan Raffit¹,Miller Andrew C.²,Sharon Elad³,Thomas Anish⁴,Reynolds James C.⁵,Ling Alexander⁵,Kreitman Robert J.¹,Miettinen Markku M.⁶,Steinberg Seth M.⁷,Fowler Daniel H.⁸,Pastan Ira¹

Affiliation:

1. Laboratory of Molecular Biology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

2. Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA.

3. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD 20892, USA.

4. Medical Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.

5. Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD 20892, USA.

6. Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD 20892, USA.

7. Biostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, MD 20892, USA.

8. Experimental Transplantation and Immunology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.

Abstract

In patients with advanced chemotherapy-refractory mesothelioma, treatment with the anti-mesothelin immunotoxin SS1P and immunosuppression with pentostatin and cyclophosphamide resulted in marked and durable tumor regressions.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference25 articles.

1. Advances in Malignant Mesothelioma

2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

3. Malignant Pleural Mesothelioma

4. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

5. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Targeted Therapy in Mesotheliomas: Uphill All the Way;Cancers;2024-05-22

3. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers;Frontiers in Oncology;2024-04-19

4. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET;Journal of Experimental & Clinical Cancer Research;2024-04-03

5. Enhanced delivery of protein therapeutics with a diphtheria toxin-like platform that evades pre-existing neutralizing immunity;2024-04-02